Find research datasets worth reusing

opencc-by-4.0Mar 2024View details →

Biomarkers in Metastatic Castration-Resistant Prostate Cancer for efficiency of Immune Checkpoint Inhibitors

Open the record for dataset details and reuse information.

opencc-by-4.0Dec 2021View details →

Datasets: Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling

Zipped NMR datasets: data1     LNCaP medium with [U-13C4]aspartate data2     LNCaP medium with [1,6-13C2]glucose data3     LNCaP medium with [2-13C]pyruvate data4     VCaP medium with [1,6-13C2]glucose data5     VCaP medium with [U-13C4]aspartate -glucose +pyruvate data6     VCaP medium with [5-13C]glutamine data7     VCaP medium with [2-13C]pyruvate -glucose +aspartate data8     VCaP medium with [5-13C]glutamine data9     VCaP medium with [5-13C]glutamine data10  VCaP medium with [5-13C]glutamine data11  LNCaP and VCaP medium with and without zinc(II) data12  LNCaP and VCaP medium with and without zinc(II) data13  LNCaP and VCaP medium with and without zinc(II) data14  LNCaP medium with [U-13C4]aspartate -glucose +pyruvate data15  LNCaP medium with [5-13C]glutamine data16  LNCaP medium with [2-13C]pyruvate data17  LNCaP medium with [5-13C]glutamine data18  VCaP medium with [1,6-13C2]glucose data19  VCaP medium with [1,6-13C2]glucose data20  VCaP medium with [2-13C]pyruvate data21  LNCaP medium with [2-13C]pyruvate data22  LNCaP medium with [2-13C]pyruvate +citr. Spiking data23  LNCaP medium with [5-13C]glutamine data24  LNCaP medium with [5-13C]glutamine data25  LNCaP medium with [2-13C]pyruvate data26  VCaP medium with [2-13C]pyruvate data27  VCaP medium with [2-13C]pyruvate -glucose +aspartate data28  VCaP medium with [U-13C4]aspartate -glucose +pyruvate data29  LNCaP medium with [2-13C]pyruvate data30  LNCaP medium with [2-13C]pyruvate data31  LNCaP medium with [2-13C]pyruvate data32  VCaP medium with [2-13C]pyruvate -glucose +aspartate data33  VCaP medium with [U-13C4]aspartate -glucose +pyruvate data34  VCaP medium with [U-13C4]aspartate -glucose +pyruvate data35  LNCaP medium with [U-13C4]aspartate data36  VCaP medium with [U-13C4]aspartate -glucose +pyruvate data37  LNCaP medium with [5-13C]glutamine + citr. spiking

opencc-by-4.0Jan 2022View details →

Roles of m5C RNA modification patterns in biochemical recurrence and tumor microenvironment characterization of prostate cancer

The datasets included in the manuscript 'Roles of m5C RNA modification patterns in biochemical recurrence and tumor microenvironment characterization of prostate cancer'

opencc-ncApr 2022View details →

Development of a multivariable risk model integrating urinary peptide metabolites and Extracellular Vesicle RNA data to detect significant prostate cancer

The aim of this study was to investigate whether the robust integration of expression data from urinary extracellular vesicle RNA (EV-RNA) with urine proteomic metabolites can accurately predict PCa biopsy outcome. Urine samples were analyzed by mass spectrometry and NanoString gene-expression analysis. As a result, four classifiers were generated: ‘MassSpec’ (CE-MS proteomics), ‘EV-RNA’, ‘SoC’ (standard of care) and ‘ExoSpec’. The best prediction for Gs³3+4 at initial biopsy (AUC=0.83, 95% CI:0.77-0.88) was achieved by applying ‘ExoSpec’ classifier and he outperformed other predictive classifiers. In addition, the results showed that the performance of ‘ExoSpec’ could reduce unnecessary biopsies by 30%.

opencc-by-4.0Jun 2022View details →

Data of FigS1, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

Data of FigS1, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (original publication: doi: 10.3390/cancers14133074) contains the original figure as PNG-format (10.3390-cancers14133074_FigS1.PNG). The Corresponding raw data and subsequent data analysis obtained for TCGA analysis contains three files in csv-format (31003A-179400_10.3390-cancers14133074_SSDHRS7_23_2-1-3 .csv), three files in sps-format (31003A-179400_10.3390-cancers14133074_SSDHRS7_23_2-1-3 .sps), all further related information provided as one meta-data-file in pdf-format (31003A-179400_10.3390-cancers14133074_SSDHRS7_23_2_M1.pdf)  and one in txt-format (31003A-179400_10.3390-cancers14133074_SSDHRS7_23_2_M.txt).

opencc-by-4.0Aug 2022View details →

Bacterial RNA Virus MS2 Exposure Increases the Expression of Cancer Progression genes in LNCaP Prostate Cancer Cell Line

Supplementary Figure 1. Network of protein-protein interactions in LNCaP cells according to their interaction with T4 and M13 phages (DNA phages). The network of protein-protein interactions in Homo Sapiens was constructed using the string protein-protein interaction network v 11.5 [35] with the overexpressed genes (highest confidence level setting) in LNCaP cells. Interactions of overexpressed protein genes were mapped with the highest confidence cut-off of (0.7-0.9). In the resulting protein association network, proteins are presented as nodes connected by lines with varying thicknesses representing the highest confidence level of (0.7-0.9). It is observed that there is strong experimentally determining evidence for the link between SRC and other overexpressed genes, including MAPKs and other integrins by adding more nodes until the highest confidence level of (0.7-0.9) among all overexpressed genes was obtained based on known interactions.   Supplementary Figure 2. Enrichr web server-based gene set enrichment analysis for overexpressed cancer progression genes in LNCaP cells treated with (A) MS2 and (B) T4 and M13 phages; which predicts caveolin-mediated endocytosis for MS2 bacterial virus (with a p-value of 0.000001399). Similarly, an integrin-mediated signaling pathway (with a p-value of 0.000007588) based on overexpression of most integrin genes and caveolin-mediated endocytosis (with a p-value of 0.000001799) were predicted for both T4 and M13 phages based on GO Biological process 2021.

opencc-by-4.0Aug 2021View details →

Synergistic antitumor interaction of valproic acid and simvastatin and docetaxel in Prostate cancer cells

Synergistic antitumor interaction of valproic acid, simvastatin and docetaxel in prostate cancer cells on cell migration, cell cycle perturbation, apoptosis, 3D cell culture models and stem marker reduction in in vivo model.

Fig. 2 in Synthesis of bilocularin A carbamate derivatives and their evaluation as leucine transport inhibitors in prostate cancer cells

Fig. 2. COSY (in green) and key HMBC (in red) correlations of compound 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 4 in Synthesis of bilocularin A carbamate derivatives and their evaluation as leucine transport inhibitors in prostate cancer cells

Fig. 4. Effects of compounds 1–9 on cell viability and leucine uptake in LNCaP cells (a) MTT cell growth assay was performed in LNCaP cells treated with compounds 1–9 at 20 μM for 72 h (n = 3, mean ± SEM) (b) [3H]-L-leucine uptake was performed using 20 μM of compounds 1–9 in LNCaP cells (n = 3, mean ± SEM). Asterisks represent Pvalues: *P ⩽ 0.05; ***P ⩽ 0.001 for one-way analysis of variance by Dunnett's multiple comparison test (c) [3H]-L-leucine uptake was performed at varying doses of compounds 4 and 5 to determine the IC50 values (n = 3, mean ± SEM).

Fig. 3 in Synthesis of bilocularin A carbamate derivatives and their evaluation as leucine transport inhibitors in prostate cancer cells

Fig. 3. ORTEP of bilocularin A carbamate analogue 7; Hydrogen atoms, EtOH and H2O molecules are omitted for clarity.

Fig. 1. Derivatisation reaction conditions for bilocularin A in Synthesis of bilocularin A carbamate derivatives and their evaluation as leucine transport inhibitors in prostate cancer cells

Fig. 1. Derivatisation reaction conditions for bilocularin A (1) and the resulting semi-synthetic carbamate library (2–9).

opencc-by-4.0Aug 2024View details →

1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia

This dataset was collected from patients diagnosed with prostate cancer (R-sample_number) and benign prostatic hyperplasia (T-sample_number) using 1H-NMR spectroscopy. For more details check our paper: https://doi.org/10.1016/j.heliyon.2024.e28949

Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men

ClinicalTrials.gov study NCT04108871. IPD Sharing: Not stated. Countries: 1. Publications: 8.

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov study NCT04862091. IPD Sharing: Not stated. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →

SBRT for Oligometastatic Castration-Refractory Prostate Cancer

ClinicalTrials.gov study NCT02816983. IPD Sharing: YES. Countries: 1. Publications: 1.

S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate

ClinicalTrials.gov study NCT00030901. IPD Sharing: Not stated. Countries: 0. Publications: 1.

closedIPD-NOFeb 2026View details →

Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

ClinicalTrials.gov study NCT05224869. IPD Sharing: NO. Countries: 1. Publications: 1.

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

ClinicalTrials.gov study NCT01366053. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

ClinicalTrials.gov study NCT05249712. IPD Sharing: Not stated. Countries: 1. Publications: 1.